Navigation Links
Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance
Date:10/27/2011

CHADDS FORD, Pa., Oct. 27, 2011 /PRNewswire/ --

  • Total quarterly revenues of $759 million increase 71 percent versus prior year; branded pharmaceuticals revenues grow 17 Percent, reflecting strong performance of OPANA® ER, Voltaren® Gel and LIDODERM®;
  • Reported quarterly diluted EPS of $0.34 versus $0.46 for prior year
  • Adjusted diluted EPS of $1.25 reflecting growth of 45 percent from 2010
  • Company reaffirms 2011 guidance for revenue of $2.72 to $2.80 billion and adjusted diluted EPS of $4.55 to $4.65; now expects reported or GAAP diluted EPS of $1.87 to $1.97
  • Company makes progress on integration and build-out of its urology franchise  

    • Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the third quarter of 2011.

    Total revenues during the third quarter of 2011 increased 71 percent to $759.1 million, compared with $444.1 million in the same quarter of 2010.  Net income for the three months ended Sept. 30, 2011, was $40.6 million, compared with $54.2 million in the comparable 2010 period.  

    Additionally, adjusted net income for the three months ended Sept. 30, 2011, was $151.1 million, up 50 percent compared with $100.8 million in the same period in 2010.  Reported diluted earnings per share for the quarter ended Sept. 30, 2011, were $0.34 compared with $0.46 reported in the third quarter of 2010. Adjusted diluted earnings per share for the same period were $1.25, up 45 percent from $0.86 reported in 2010.

    "Endo had another strong quarter, with record revenues and adjusted earnings, led by Opana ER, generics and AMS's Men's Health business," said Dave Holveck, president and CEO of Endo. "This performance is a testament to our diversified business model, and our commitment to enhancing heal
    '/>"/>

    SOURCE Endo Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... , May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... study, JAKARTA , examining the selective ... endpoint in both dose groups. The primary endpoint assessed ... volume. Consistent with data reported in previous trials, the ... vomiting. Full results will be presented at an upcoming ...
    (Date:5/17/2013)... May 17, 2013  Boston Scientific Corporation (NYSE: ... annual EuroPCR Scientific Program May 21-24 in ... present a particularly rich and diversified set of data ... , M.D., global chief medical officer, Boston Scientific.  ... presented, including the NG PROMUS trial, which evaluated our ...
    (Date:5/16/2013)...  PTC Therapeutics, Inc., today announced that it has ... U.S. Securities and Exchange Commission ("SEC") relating to the ... number of shares to be offered and the price ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) J.P. ... managers for the offering. Cowen and Company is acting ...
    Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
    ... TRIANGLE PARK, N.C. , May 6 Chimerix, Inc., ... Thomas A. Pitler , Ph.D., has joined the company as Vice ... , , ... of experience, combining skills in business development and strategic planning with ...
    ... Intercell AG (VSE: ICLL) today announced that it has signed an agreement ... discovery. The technology is based on expression cloning of monoclonal antibodies from ... treat infectious diseases. , , ... the agreed terms Intercell will pay EUR 15 million to ...
    Cached Medicine Technology:Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development 2Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development 3Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases 2
    (Date:5/19/2013)... Chicago, IL (PRWEB) May 19, 2013 In ... Surge, LLC, E-dentist.com has announced the launch of an SEO ... help dentists get high rankings in Google. , http://www.e-dentists.com/ ... do not pay for the service until they see results. ... sites. The lead generation websites run by JD Media Surge, ...
    (Date:5/19/2013)... 19, 2013 According to a ... and Forecast (2013 – 2018): By Applications (Healthcare ... Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) And ... sensor market was $8.00 billion in 2012 and ... at an estimated CAGR of 3.84% from 2013 ...
    (Date:5/19/2013)... The Pradaxa lawyers at Bernstein Liebhard ... convened for hundreds of Pradaxa bleeding lawsuits ... U.S. District Court, Southern District of Illinois. According ... 14th, the Conference addressed the status of depositions and ... Conference that Defendants submitted a list of early trial ...
    (Date:5/19/2013)... 2013 Vegas Hotel Escapes, the premier ... announce the launch it's all new vacation packages for ... on 5/19/2013. Consumers traveling to Las Vegas will be ... on VegasHotelEscapes.com's website. Travelers will be pleased to know ... price. , Vegas Hotel Escapes specializes in helping consumers ...
    (Date:5/19/2013)... Rockford, IL (PRWEB) May 19, 2013 Beginning ... Rock River Valley Blood Center (RRVBC) will feature “Hot Dog ... and Belvidere. RRVBC will provide hot dogs and all ... feature ice-cold slushies each day throughout the summer. “Donors are ... to maintain a stable and adequate blood supply. This ...
    Breaking Medicine News(10 mins):Health News:Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2
    ... ... Two books provide a new way ... Literacy" is designed for teachers, and "HandMade Marks" is designed ... evaluation tools, hands-on exercises, and research questions, while also addressing ...
    ... ... UC-II®, is included in a new product from Nordic Naturals, the industry leader in ... 2010 Natural Products Expo West with great feedback from attendees looking for the latest, ... ...
    ... Those with abnormalities at initial screening often didn,t have ... News) -- Black Americans are less likely than whites ... on a flexible sigmoidoscopy screening test, says a new ... be at greater risk for colorectal cancer and more ...
    ... frequent returns to hospital for treatment, at higher rates than ... sickle cell disease often visit hospitals repeatedly in search of ... researchers found that one-third of sickle cell patients who visited ... relief. Young people, between the ages of 18 and 30, ...
    ... Mich.---The proportion of older middle-aged Americans who report disabilities ... in contrast to the disability decline that has been ... a new study by the RAND Corporation and the ... the proportion of Americans aged 50 to 64 who ...
    ... LOUIS -- In a broad-based review of studies focused on ... no evidence supporting the use of so-called "natural" treatments in ... wort, kava extract and valerian, herbal remedies touted on the ... anxiety wrote Kimberly Zoberi, M.D., associate professor of family and ...
    Cached Medicine News:Health News:The Child's Way into Literacy: A New Look at Scribbling and Drawing 2Health News:InterHealth's UC-II in New Joint-Health Product from Nordic Naturals 2Health News:InterHealth's UC-II in New Joint-Health Product from Nordic Naturals 3Health News:InterHealth's UC-II in New Joint-Health Product from Nordic Naturals 4Health News:Blacks Less Likely to Get Follow-Up Colon Screening 2Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 2Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 3Health News:Middle-aged Americans report more mobility-related disabilities 2Health News:Middle-aged Americans report more mobility-related disabilities 3
    ... Respiratory Products, ,Westmed designs, manufacturers and ... and Respiratory professionals. Our mission is to ... clinician's ability to deliver quality medical care ... line. , ,Our web site is ...
    ... achieves optimum lung penetration for maximum therapeutic ... 1.04-1.10 µ at 6-8 LPM. Latex-free components. ... ,As the world leader in airway management ... of proven technology by offering top brands ...
    ... need for makeshift, modified nebulizer setups to ... gathering parts when your patient is critical? ... the utmost in Heliox rescue therapy. In ... becoming the standard of care in hospitals ...
    ... nebulizers offer a spill-proof design and effective ... 45° angle. All medical nebulizers are free-standing ... of configurations are available., ,All Portex® ... ,Portex® medication nebulizers feature consistently fine misting ...
    Medicine Products: